A carregar...

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Korean J Intern Med
Main Authors: Lee, Hyo Young, Jun, Dae Won, Kim, Hyun Jung, Oh, Hyunwoo, Saeed, Waqar Khalid, Ahn, Hyeongsik, Cheung, Ramsey C., Nguyen, Mindie H.
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Association of Internal Medicine 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6406097/
https://ncbi.nlm.nih.gov/pubmed/29551054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2017.194
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!